Circulation Research, Vol 68, 1722-1728, Copyright © 1991 by American Heart Association

ARTICLES

S-nitrosocysteine inhibition of human platelet secretion is correlated with increases in platelet cGMP levels

EH Lieberman, S O'Neill and ME Mendelsohn
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.

Platelet inhibition by exogenous and endogenous nitrovasodilators has been shown to be associated with increases in cGMP, but proof of a role for cGMP in this process is lacking. We therefore studied the effects of cGMP and guanylate cyclase stimulation on human platelet secretion by pharmacologically modulating intraplatelet cGMP levels. The endothelium-derived relaxing factor (EDRF)-like activator of guanylate cyclase, S-nitrosocysteine (SNOC), led to a dose-dependent inhibition of secretion in intact human platelets (IC50 = 10(-6) M). The cGMP phosphodiesterase inhibitor M&B 22,948 augmented SNOC-induced inhibition of secretion through elevations in cGMP without affecting cAMP levels (from 50% to 81% inhibition versus control, p = 0.02). Methylene blue reversed the inhibitory effects of SNOC on platelet secretion (p = 0.03). Dibutyryl-cGMP and 8-bromo-cGMP also significantly inhibited secretion in this system. Incubation of platelets with exogenous cGMP to achieve intraplatelet cGMP levels comparable to those after SNOC treatment resulted in similar degrees of inhibition of secretion (32% inhibition versus control, p = 0.01) and was also potentiated by M&B 22,948 (from 32% to 68% inhibition, p = 0.003). In addition, a highly significant correlation between intraplatelet cGMP levels and the degree of inhibition of secretion was demonstrable in these studies (r = 0.94, p = 0.016). These data demonstrate that elevation of intraplatelet cGMP levels by the EDRF- like compound SNOC is correlated with inhibition of human platelet secretion.

This article has been cited by other articles:

				H. M. Reid and B. T. Kinsella The {alpha}, but Not the {beta}, Isoform of the Human Thromboxane A2 Receptor Is a Target for Nitric Oxide-mediated Desensitization: INDEPENDENT MODULATION OF TP{alpha} SIGNALING BY NITRIC OXIDE AND PROSTACYCLIN J. Biol. Chem., December 19, 2003; 278(51): 51190 - 51202. [Abstract] [Full Text] [PDF]

				J. G. Diodati, N. Dakak, D. M. Gilligan, and A. A. Quyyumi Effect of Atherosclerosis on Endothelium-Dependent Inhibition of Platelet Activation in Humans Circulation, July 7, 1998; 98(1): 17 - 24. [Abstract] [Full Text] [PDF]

				Y. Nakano, T. Oshima, H. Matsuura, G. Kajiyama, and M. Kambe Effect of 17ß-Estradiol on Inhibition of Platelet Aggregation In Vitro Is Mediated by an Increase in NO Synthesis Arterioscler Thromb Vasc Biol, June 1, 1998; 18(6): 961 - 967. [Abstract] [Full Text] [PDF]

				G.-R. Wang, Y. Zhu, P. V. Halushka, T. M. Lincoln, and M. E. Mendelsohn Mechanism of platelet inhibition by nitric oxide: In vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase PNAS, April 28, 1998; 95(9): 4888 - 4893. [Abstract] [Full Text] [PDF]

				K. Krejcy, L. Schmetterer, J. Kastner, M. Nieszpaur-Los, B. Monitzer, W. Schutz, H.-G. Eichler, and P. A. Kyrle Role of Nitric Oxide in Hemostatic System Activation In Vivo in Humans Arterioscler Thromb Vasc Biol, November 1, 1995; 15(11): 2063 - 2067. [Abstract] [Full Text]

				M.-T. Walsh, J. F. Foley, and B. T. Kinsella The alpha , but Not the beta , Isoform of the Human Thromboxane A2 Receptor Is a Target for Prostacyclin-mediated Desensitization J. Biol. Chem., June 30, 2000; 275(27): 20412 - 20423. [Abstract] [Full Text] [PDF]